Back to Search
Start Over
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
- Source :
- European Journal of Pharmacology, 763, 48-63
- Publication Year :
- 2015
-
Abstract
- Non-HDL-cholesterol is well recognised as a primary causal risk factor in cardiovascular disease. However, despite consistent epidemiological evidence for an inverse association between HDL-C and coronary heart disease, clinical trials aimed at raising HDL-C (AIM-HIGH, HPS2-THRIVE, dal-OUTCOMES) failed to meet their primary goals. This systematic review and meta-analysis investigated the effects of established and novel treatment strategies, specifically targeting HDL, on inhibition of atherosclerosis in cholesteryl ester transfer protein-expressing animals, and the prevention of clinical events in randomised controlled trials. Linear regression analyses using data from preclinical studies revealed associations for TC and non-HDL-C and lesion area (R2=0.258, P=0.045; R2=0.760, P
- Subjects :
- Apolipoprotein A-I inducer
Drug targeting
ATP binding cassette A1 degradation inhibitor
Mouse
Unclassified drug
Glitazone derivative
Low density lipoprotein cholesterol
Biomedical Innovation
Rabbit
Reconstituted HDL
Treatment response
Cardiovascular agent
Clinical trials
Delipidated HDL
Randomized controlled trial (topic)
Life
ABCA1 degradation inhibitors
LDL-cholesterol
High density lipoprotein cholesterol
Peroxisome proliferator activated receptor agonist
Scavenger receptor BI inhibitor
Apolipoprotein A-I Milano
Clinical outcome
Fibric acid derivative
Cardiovascular disease
Peptide derivative
HDL-cholesterol
Nicotinic acid
Cholesterol blood level
Clinical trial (topic)
Cholesterol ester transfer protein inhibitor
lipids (amino acids, peptides, and proteins)
Cholesterol ester transfer protein
MHR - Metabolic Health Research
Healthy Living
APOE
Human
SR-BI inhibitor
3Leiden.CETP mice
LCAT
Non-HDL-cholesterol
Niacin
Glitazar derivative
Adverse outcome
Disease association
Dalcetrapib
Apolipoprotein A-I mimetic
Hamster
Mortality
Receptor blocking agent
Biology
Placebo
PPAR agonists
Liver X receptor agonist
Glitazones
Agents affecting lipid metabolism
Atherosclerosis
Cardiovascular risk
Nonhuman
Drug effect
Myocardial infarction
Risk management
Risk reduction
Systematic review
Protein expression
Heart infarction
ELSS - Earth, Life and Social Sciences
Fibrates
Meta analysis
CETP inhibition
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- European Journal of Pharmacology, 763, 48-63
- Accession number :
- edsair.dedup.wf.001..6c7d5a245e65517c8f0828e9218edc9f